Quanzhou Haichuang Pharmaceutical Technology

Quanzhou Haichuang Pharmaceutical Technology is a specialized subsidiary of Hinova Pharmaceuticals, established in 2020 and located in Quanzhou, China. The company functions as a strategic research, development, and manufacturing hub dedicated to advancing Hinova's pipeline of innovative small molecule therapeutics. Its core technological focus includes deuteration and Proteolysis Targeting Chimera (PROTAC) platforms, which are applied to address unmet needs in oncology and metabolic diseases. Quanzhou Haichuang is instrumental in the industrialization of key assets such as HC-1119, a deuterated androgen receptor antagonist for prostate cancer, and HP518, an oral PROTAC degrader. The facility is designed to meet international GMP standards to support both domestic and global clinical trials and commercial supply.